Peter Zdziarski/LinkedIn
Feb 18, 2026, 15:24
Peter Zdziarski: How Glanzmann Thrombasthenia Suddenly Became ‘Mainstream’?
Peter Zdziarski, Vice President and Marketing Director at Glanzmann’s Research Foundation, shared a post on LinkedIn։
”Recently posted in the incredible Glanzmann Thrombasthenia Support Group (with almost 1 thousand patients, family members, and doctors!)
Just thinking out loud:
Has anyone else noticed how GT suddenly became ‘mainstream’?
And just as fast, a wave of unknown experts showed up out of nowhere?
I wish I knew why, but the point is this:
You are the expert in your GT. Your lived experience matters more than any trending take.
I know our community has been cautious about attention in the past. But let’s take advantage of the spotlight and turn it into new treatments and possibly even gene therapy!”
Stay updated with Hemostasis Today.
-
Apr 5, 2026, 05:32Preeti Sinha: Molecular Mechanisms of Atherosclerosis
-
Apr 5, 2026, 05:28Alessandra Bosch: Exploring Haemostasis in Children
-
Apr 5, 2026, 05:19Chris Centeno: Why Regular Blood Therapy Could Boost Aging MSK Health
-
Apr 4, 2026, 18:08Anirban Sen Gupta: Dante Disharoon’s Research on PlateChek Featured on JTH April 2026 Cover
-
Apr 4, 2026, 18:06Domenico Girelli: WHO 2024 Guidelines Reveal Higher Global Anemia Burden and Epidemiological Shift
-
Apr 4, 2026, 18:04Fotios Barkas: Exploring The Bidirectional Relationship Between Frailty and Stroke
-
Apr 4, 2026, 17:56Marc Turner: VETERANSFirst, CHAMPION-AF Trial, and HI-PEITHO Trial Driving Innovation at ACC26
-
Apr 4, 2026, 17:55Julian Kyoung-Ryul Chun: The Largest Dataset on Embolic Complications after AF Is Out
-
Apr 4, 2026, 17:54Marie Dragoy: Insights from Norway on Helicopter Emergency Services in Suspected Stroke Care